Emphasis on neoadjuvant therapy for “resectable”pancreatic cancer
-
摘要: 胰腺癌的治疗理念正由"surgery first"向多学科综合治疗模式转变,其术后辅助治疗可显著改善患者预后,已为目前诊疗规范;但新辅助治疗的价值和意义尚不明确。针对"可能切除"的胰腺癌,有限临床研究表明,新辅助治疗可提高R0切除率,改善患者预后,推荐开展应用。但在应用指征、周期及方案选择等方面,缺乏共识,因此新辅助治疗在"可切除"胰腺癌中的意义存在较大争议,亟待开展前瞻性对照研究,以客观评价新辅助治疗对改善"可切除"胰腺癌患者预后的价值和作用。Abstract: The treatment concept for pancreatic cancer is being transferred from“surgery first”to MDT model.The postoperative adjuvant treatment of pancreatic cancer can significantly improve the prognosis of patients and has become the standardized diagnostic and treatment practice; the value and significance of neoadjuvant therapy remains unclear.Limited clinical studies of “borderline resectable”pancreatic cancer have shown that neoadjuvant therapy can improve the R0 resection rate and improve the prognosis of patients,and it is recommended for clinical application.But the significance of neoadjuvant therapy in“resectable”pancreatic cancer is still controversial.There is a lack of consensus on indications,cycles,and regimens.It is necessary to carry out a series of prospective control studies to objectively evaluate the value of neoadjuvant therapy in improving the prognosis of“resectable”pancreatic cancer.
-
Key words:
- pancreatic neoplasms /
- neoadjuvant therapy /
- editorial
本文二维码
计量
- 文章访问数: 1994
- HTML全文浏览量: 7
- PDF下载量: 507
- 被引次数: 0